Search for: "MAJOR PHARMACEUTICALS" Results 601 - 620 of 4,361
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Jul 2021, 3:11 am by Kluwer Patent blogger
Beyond that, the Basic Law does not confer a right upon citizens that would allow them to subject all majority decisions taken by Parliament to a review of lawfulness. [read post]
  Further, it is not just Ericsson’s SEPs that could have been affected – the evidence before the court showed that, like Ericsson, the vast majority of SEP holders (including Apple) made “late” IPR declarations. [read post]
8 Jul 2021, 4:27 am by Florence Campbell Jones
Treatment and prevention of cardiovascular diseases and its major risk factors, including obesity. [read post]
8 Jul 2021, 1:18 am by Sarah Khan
 Note that the consultation does not cover some major topics such as: ● Exhaustion of rights in purely digital goods. [read post]
8 Jul 2021, 1:18 am by Sarah Khan
 Note that the consultation does not cover some major topics such as: ● Exhaustion of rights in purely digital goods. [read post]
The majority’s goal is to combat unlawful business processes across the economy, especially in the COVID-19 arena and technology, labor, digital platforms, healthcare, and pharmaceutical sectors, and, furthermore, to crack down on repeat offenders and closely monitor mergers. [read post]
3 Jul 2021, 12:47 pm by Peter S. Lubin and Patrick Austermuehle
The ruling is also likely to affect antitrust enforcement in the pharmaceutical industry where the FTC has pursued disgorgement amounts as high as $1.2 billion. [read post]
2 Jul 2021, 11:39 pm by Kluwer Patent blogger
“The Annual Review 2020 shows that demand for European patents remained nearly on a par with last year. [read post]
1 Jul 2021, 9:03 pm by Katelynn Catalano
Madl concluded that heightened scrutiny of below-threshold pharmaceutical acquisitions by the FTC is not necessary. [read post]
24 Jun 2021, 6:23 am by Holly Buckley
Within healthcare, the firm targets companies in the provider services, hospital/major facilities and life sciences/pharmaceutical industries. [read post]
18 Jun 2021, 7:47 am by Kevin LaCroix
  ************************* On June 16, 2021, the Third Circuit Court of Appeals issued a precedential decision in the high-profile Valeant Pharmaceuticals securities litigation. [read post]
17 Jun 2021, 12:31 pm by luiza
Read More: Data Analysts: a New Kind of Whistleblower to “Catch a Rogue” Data Whistleblower Case Raises Question of What is a Public Disclosure Healthcare and Pharmaceutical Fraud The False Claims Act Whistleblower FAQs Contact us for a confidential consultation. [read post]
15 Jun 2021, 9:13 am by Robbie Kenney
Today Comar is a major player globally, with eight manufacturing facilities in the U.S. and Puerto Rico. [read post]
13 Jun 2021, 3:04 am by Edward Smith
The first major verdict resulting from these claims was in 2018 in the case of Johnson v. [read post]
10 Jun 2021, 1:56 pm by Joe Mullin
Just a tiny slice of universities earn the majority of patent-licensing revenue, often from a few blockbuster pharmaceutical or biotech inventions. [read post]
9 Jun 2021, 6:00 am by Jane Turner
Kitchen had never seen major currencies move by that amount, and knew that there had been manipulation by major players, traders, and banks using illegal robotic trading. [read post]
6 Jun 2021, 9:03 pm by Scott Burris
There was a vaccine, but industrial pharmaceutical production was in its infancy, and anti-vaccine sentiment was widespread. [read post]
3 Jun 2021, 5:29 am by Florian Mueller
" That's going to be the message.For chemical and pharmaceutical companies, however, it's going to be an annoyance at best and a source of legal uncertainty at worst.That's because in cases where they are not interested in a license deal--not even in the slightest--but want to get a plagiarist enjoined, there won't be a licensing offer on the table. [read post]
31 May 2021, 7:51 pm by Peter Mahler
Background The complaint in Shilpa basically alleged that the defendant majority shareholders of InvaGen Pharmaceuticals, Inc., a Long Island-based generic pharmaceutical company, cheated the plaintiff minority shareholder out of $14.3 million in proceeds from the sale of InvaGen to a multinational pharmaceutical company. [read post]